Compare iShares MSCI Australia ETF (EWA) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Smith & Nephew plc — how do they compare? iShares MSCI Australia ETF trades at $29.94, while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: Smith & Nephew plc pays a 2.64% dividend while iShares MSCI Australia ETF pays none, and iShares MSCI Australia ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| EWA | SNN | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.41 | $38.70 |
52-Week Low | $24.95 | $28.73 |
Market Cap | — | $12.50B |
Enterprise Value | — | $15.53B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $30.41, up 0.83% with a bullish technical bias from moving averages, though oscillators signal caution with RSI levels above 70 indicating potential overbought conditions. The stock shows strong momentum with ADX readings above 36, while support and resistance cluster near $30-$31. Recent corporate actions include a scheduled dividend of $0.40 per share for June 2026.
Outlook remains positive given technical strength, but elevated RSI warrants monitoring for pullbacks. Risks include macroeconomic sensitivity and sector competition. Investment appeal hinges on sustained earnings growth and dividend stability, with current levels offering limited upside near resistance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
